Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna today and set a price target of $18.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mani Foroohar has given his Sell rating due to a combination of factors impacting Moderna’s financial outlook. The company has announced a significant term loan facility, which increases its cash guidance but also raises concerns about its reliance on debt financing. This move, while potentially beneficial for capital costs, highlights the company’s vulnerability in ongoing intellectual property litigation, which could result in substantial financial liabilities.
Additionally, Moderna’s revenue guidance for the upcoming years remains modest, with expectations of only 10% growth in 2026 driven by specific partnerships and product uptake. The company’s efforts to optimize costs and improve margins are noted, but the discontinuation of several R&D programs and the pause of early-stage projects until cash break-even is achieved by 2028, suggest a cautious approach to future growth. These factors collectively contribute to a less optimistic view of Moderna’s stock performance.
In another report released yesterday, Wolfe Research also reiterated a Sell rating on the stock with a $17.00 price target.